Test Article
|
Matrix
|
Species
|
Anticoagulant
|
Assay Type
|
LLOQ-ULOQ
|
4-Hydroxycyclophosphamide |
Plasma |
Human |
Heparin |
LC-MS/MS |
5-500 |
4-Ketocyclophosphamide |
Plasma |
Human |
Heparin |
LC-MS/MS |
0.1-10 |
Abiraterone |
Plasma |
Human |
EDTA/Heparin |
LC-MS/MS |
0.5-420 |
Bendamustine and M3 and M4 Metabolites |
Plasma |
Human |
Heparin |
LC-MS/MS |
1-1000 |
Bortezomib |
Plasma |
Human |
Heparin |
LC-MS/MS |
1-250 |
Capecitabine and Metabolites (Prodrug for 5-Fluorouracil) |
Plasma |
Human |
Heparin |
LC-MS/MS |
75-10000 |
Cyclophosphamide |
Plasma |
Human |
Heparin |
LC-MS/MS |
250-25000 |
Cyclophosphamide |
Plasma |
Human |
Heparin |
LC-MS/MS |
1-100 |
Daunorubicin |
Plasma |
Human |
EDTA |
LC-MS/MS |
1-1000 |
Dechloroethylcyclophosphamide |
Plasma |
Human |
Heparin |
LC-MS/MS |
0.1-10 |
Docetaxel |
Plasma Ultrafiltrate |
Human |
Heparin |
LC-MS/MS |
2-100 |
Docetaxel |
Plasma |
Human |
EDTA/Heparin |
LC-MS/MS |
1-1000 |
Docetaxel |
Plasma Ultrafiltrate |
Human |
Heparin |
LC-MS/MS |
2-100 |
Docetaxel |
Plasma |
Mouse |
Heparin |
LC-MS/MS |
50-5000 |
Docetaxel |
Plasma |
Dog |
Heparin |
LC-MS/MS |
10-2500 |
Docetaxel |
Plasma |
Human |
Heparin |
LC-MS/MS |
10-2500 |
Docetaxel |
Plasma |
Human |
Heparin |
LC-MS/MS |
10 |
Doxorubicin |
Plasma |
Human |
EDTA |
LC-MS/MS |
1-1000 |
Gemcitabine |
Plasma |
Human |
EDTA |
LC-MS/MS |
1-1000 |
Gemcitabine and 2’,2’-Difluoro-2’-Deoxyuridine (dFdU) Metabolite |
Plasma (THU-treated) |
Human |
Heparin |
LC-MS/MS |
50-50000 |
Lenalidomide |
Plasma |
Human |
EDTA |
LC-MS/MS |
1-1000 |
Methotrexate and 7-Hydroxymethotrexate Metabolite |
Plasma |
Human |
Heparin |
LC-MS/MS |
1-1000 |
Methotrexate and 7-Hydroxymethotrexate Metabolite |
Urine |
Human |
None |
LC-MS/MS |
20-10000 |
Octenidine |
Plasma |
Human |
EDTA |
LC-MS/MS |
1-10 |
Paclitaxel |
Seminal Fluid |
Human |
None |
LC-MS/MS |
0.1-100 |
Paclitaxel |
Urine |
Human |
None |
LC-MS/MS |
0.1-100 |
Paclitaxel |
Plasma |
Dog |
Heparin |
LC-MS/MS |
0.1-100 |
Paclitaxel |
Urethral and Prostate Tissues |
Dog |
None |
LC-MS/MS |
0.3-300 |
Paclitaxel |
Urethral and Prostate Tissues |
Dog |
None |
LC-MS/MS |
0.3-400 |
Paclitaxel |
Plasma |
Human |
EDTA |
LC-MS/MS |
5-5000 |
Paclitaxel |
Plasma |
Rat |
Heparin |
LC-MS/MS |
0.1-100 |
Paclitaxel |
Arterial Tissue |
Porcine |
None |
LC-MS/MS |
0.5-500 |
Paclitaxel |
Plasma |
Human |
Heparin |
LC-MS/MS |
20-5000 |
Paclitaxel |
Seminal Fluid |
Human |
None |
LC-MS/MS |
0.1-100 |
Paclitaxel |
Plasma Ultrafiltrate |
Dog |
EDTA |
LC-MS/MS |
0.3-1000 |
Paclitaxel |
Serum |
Porcine |
None |
LC-MS/MS |
0.03-30 |
Paclitaxel |
Whole Blood |
Dog |
Heparin |
LC-MS/MS |
1-1000 |
Paclitaxel |
Whole Blood |
Porcine |
None |
LC-MS/MS |
0.03-30 |
Paclitaxel |
Urine |
Porcine |
None |
LC-MS/MS |
0.03-30 |
Paclitaxel |
Plasma |
Porcine |
EDTA/Heparin |
LC-MS/MS |
0.03-30 |
Paclitaxel |
Whole Blood |
Human |
None |
LC-MS/MS |
1-1000 |
Paclitaxel |
Plasma or Plasma Ultrafiltrate |
Human |
EDTA/Heparin |
LC-MS/MS |
0.1-1000 |
Paclitaxel |
Serum |
Mouse |
None |
LC-MS/MS |
0.3-300 |
Paclitaxel |
Serum |
Dog |
None |
LC-MS/MS |
0.03-30 |
Paclitaxel |
Plasma |
Dog |
Heparin |
LC-MS/MS |
0.1-100 |
Paclitaxel |
Serum |
Porcine |
None |
LC-MS/MS |
0.03-100 |
Paclitaxel |
Tissues |
Porcine |
None |
LC-MS/MS |
0.3-500 |
Paclitaxel |
Plasma |
Rabbit |
EDTA/Heparin |
LC-MS/MS |
0.03-30 |
Paclitaxel |
Serum |
Rabbit |
None |
LC-MS/MS |
0.03-30 |
Paclitaxel and 6α-Hydroxy Paclitaxel Metabolite |
Plasma |
Human |
EDTA |
LC-MS/MS |
1-1000 |
Paclitaxel, 3-OH-Paclitaxel, & 6-OH-Paclitaxel |
Dog & Rat Plasma |
|
Heparin |
LC-MS/MS |
0.100 |
Rapamycin |
Whole Blood (Lysed) |
Cat |
EDTA |
LC-MS/MS |
0.1-100 |
Rapamycin |
Whole Blood (Lysed) |
Monkey |
EDTA |
LC-MS/MS |
0.1-100 |
Rapamycin |
Whole Blood (Lysed) |
Monkey |
EDTA |
LC-MS/MS |
1000-40000 |
Sunitinib and N-desethyl Sunitinib |
Plasma |
v |
EDTA |
LC-MS/MS |
1-100 |
Tamoxifen |
Plasma |
Human |
Heparin |
LC-MS/MS |
0.5-500 |
Temozolomide |
Plasma |
Rat |
Heparin |
LC-MS/MS |
10-2000 |